Arcadia Biosciences (RKDA) EBIT (2014 - 2026)

Arcadia Biosciences (RKDA) has reported EBIT for 13 consecutive years, with -$496000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 1.0% year-over-year to -$496000.0; the trailing twelve-month figure through Jun 2026 stood at -$3.5 million (up 12.12% YoY), and the FY2025 full-year result was -$2.5 million, up 31.47% from the prior year.
• EBIT rose to -$496000.0 in Q2 2026 per RKDA's latest filing, from -$1.4 million in the prior quarter.
• Across five years, EBIT topped out at $2.0 million in Q2 2024 and bottomed at -$4.7 million in Q4 2022.
• Historically, EBIT has averaged -$1.9 million across 5 years, with a median of -$1.5 million in 2023.
• The sharpest annual moves came in 2024 and 2025: EBIT jumped 236.18% in 2024, then sank 125.3% in 2025.
• Over 5 years, EBIT stood at -$4.7 million in 2022, then surged by 74.39% to -$1.2 million in 2023, then sank by 91.03% to -$2.3 million in 2024, then soared by 39.67% to -$1.4 million in 2025, then surged by 63.93% to -$496000.0 in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$496000.0, -$1.4 million, and -$1.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.